Note: This thread is related to #Coronavirus #COVID19

Follow the World Health Organization's instructions to reduce your risk of infection:

1/ Frequently clean hands by using alcohol-based hand rub or soap and water.

2/ When coughing and sneezing cover mouth and nose with flexed elbow or tissue - throw issue away immediately and wash hands.

3/ Avoid close contact with anyone that has fever and cough.

Natalie E. Dean, PhD+ Your Authors @nataliexdean Assistant Professor of Biostatistics at @UF specializing in emerging infectious diseases and vaccine study design. @HarvardBiostats PhD. Tweets my own. Jun. 16, 2020 1 min read + Your Authors

Some thoughts:
- It's still too early to measure the duration and frequency of long-term complications for a new virus, but early evidence suggests they could be important.
 https://www.theatlantic.com/health/archive/2020/06/covid-19-coronavirus-longterm-symptoms-months/612679/ 
 https://www.vox.com/2020/5/8/21251899/coronavirus-long-term-effects-symptoms 

We can look at SARS or MERS and see how frequently these patients experienced long-term morbidity, but these viruses are also different. Prospective studies are being set up for COVID, although I imagine we will need more of them.
 https://www.hkmj.org/abstracts/v15n6s8/21.htm 

- IFR isn't a very useful summary statistic, as it is an average across different age/risk groups, and the age/risk profile varies from place to place. I haven't seen evidence that it is declining, but that could occur if care improves or we more effectively protect the elderly.

I would tend to advocate for an approach that stratified by age to separate out these questions. Is the profile of those infected changing? And, once infected, are people better off?

- Surveys suggest that most places still have seroprevalence below 10%, unless they have had large outbreaks. There may be cross-immunity with other coronaviruses that wouldn't be reflected in a SARS-CoV-2-specific antibody test, but we have to wonder about the magnitude.

Certainly prior circulation of other coronaviruses did not protect places like NYC or Italy from experiencing large outbreaks. Cases are rising in Saudi Arabia, where MERS has been most prevalent. So cross-immunity could help certain pockets, but it is not a strategy.

- Regarding heterogeneity and herd immunity, there are some nice replies by @joel_c_miller. I made this thread in May. My feeling is still similar. I haven't seen convincing evidence that heterogeneity could dramatically lower the threshold.

It relies on the assumption that the people most likely to get infected themselves are in turn the ones most likely to infect others. But is that true? Also, if the highly connected nodes are essential workers, and they get sick, won't they be replaced? The dynamics are complex.

Again, we can study the implications, but it is not a strategy.


You can follow @nataliexdean.



Bookmark

____
Tip: mention @threader_app on a Twitter thread with the keyword “compile” to get a link to it.

Enjoy Threader? Sign up.

Since you’re here...

... we’re asking visitors like you to make a contribution to support this independent project. In these uncertain times, access to information is vital. Threader gets 1,000,000+ visits a month and our iOS Twitter client was featured as an App of the Day by Apple. Your financial support will help two developers to keep working on this app. Everyone’s contribution, big or small, is so valuable. Support Threader by becoming premium or by donating on PayPal. Thank you.


Follow Threader